FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

GlobeNewswire

2024-10-28

HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences.

2024 ThinkEquity Conference
Date: October 30, 2024
Location: New York, NY
Format: Company Presentation
Time: 10:30 a.m. ET

BIO-Europe 2024
Date: November 5, 2024
Location: Stockholm, Sweden
Format: Company Presentation
Time: 1:30 p.m. CET

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2478485003"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2478485003\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2478485003?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-28 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478485003","market":"us","top_or_hot":-1,"title":"FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024","media":"GlobeNewswire","content":"<html><body><p>HOUSTON, Oct.  28, 2024  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a>, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences.</p> <p><strong><u>2024 ThinkEquity Conference </u></strong><br/>Date: October 30, 2024<br/>Location: New York, NY<br/>Format: Company Presentation<br/>Time: 10:30 a.m. ET</p> <p><strong><u>BIO-Europe 2024</u></strong><br/>Date: November 5, 2024<br/>Location: Stockholm, Sweden<br/>Format: Company Presentation<br/>Time: 1:30 p.m. CET</p> <p>For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.</p> <p><strong><u>About FibroBiologics</u></strong> </p> <p>Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com. </p> <p><strong>General Inquiries:</strong> <br/>info@fibrobiologics.com </p> <p><strong>Investor Relations:</strong> <br/>Nic Johnson <br/>Russo Partners <br/>(212) 845-4242 <br/>fibrobiologicsIR@russopr.com </p> <p><strong>Media Contact:</strong> <br/>Liz Phillips<br/>Russo Partners<br/>(347) 956-7697<br/>Elizabeth.phillips@russopartnersllc.com </p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/Nzk1MmU1YzEtMTI1ZC00ZjYxLTgxZjEtZjI4ODZjOGVmNDZhLTEyNzUwODE=/tiny/Fibrobiologics-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2024-10-28 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>HOUSTON, Oct.  28, 2024  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a>, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences.</p> <p><strong><u>2024 ThinkEquity Conference </u></strong><br/>Date: October 30, 2024<br/>Location: New York, NY<br/>Format: Company Presentation<br/>Time: 10:30 a.m. ET</p> <p><strong><u>BIO-Europe 2024</u></strong><br/>Date: November 5, 2024<br/>Location: Stockholm, Sweden<br/>Format: Company Presentation<br/>Time: 1:30 p.m. CET</p> <p>For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.</p> <p><strong><u>About FibroBiologics</u></strong> </p> <p>Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com. </p> <p><strong>General Inquiries:</strong> <br/>info@fibrobiologics.com </p> <p><strong>Investor Relations:</strong> <br/>Nic Johnson <br/>Russo Partners <br/>(212) 845-4242 <br/>fibrobiologicsIR@russopr.com </p> <p><strong>Media Contact:</strong> <br/>Liz Phillips<br/>Russo Partners<br/>(347) 956-7697<br/>Elizabeth.phillips@russopartnersllc.com </p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/Nzk1MmU1YzEtMTI1ZC00ZjYxLTgxZjEtZjI4ODZjOGVmNDZhLTEyNzUwODE=/tiny/Fibrobiologics-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.globenewswire.com/news-release/2024/10/28/2970153/0/en/FibroBiologics-to-Present-at-the-2024-ThinkEquity-Conference-and-BIO-Europe-2024.html","article_id":"2478485003","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478485003","pubTimestamp":1730122260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"HOUSTON, Oct.  28, 2024  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the dev","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"FibroBiologics将出席2024年ThinkEquity会议和2024年BIO-Europe","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIO":1,"FBLG":1},"content_text":"HOUSTON, Oct.  28, 2024  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences. 2024 ThinkEquity Conference Date: October 30, 2024Location: New York, NYFormat: Company PresentationTime: 10:30 a.m. ET BIO-Europe 2024Date: November 5, 2024Location: Stockholm, SwedenFormat: Company PresentationTime: 1:30 p.m. CET For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com. About FibroBiologics  Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.  General Inquiries: info@fibrobiologics.com  Investor Relations: Nic Johnson Russo Partners (212) 845-4242 fibrobiologicsIR@russopr.com  Media Contact: Liz PhillipsRusso Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}